Associate Professor of Oncology, Johns Hopkins University School of Medicine; Associate Professor of Oncology, Co-Director, Leukemia Drug Development Program
Hematology
Dr. Ivana Gojo, MD
|
|
Give Review
Dr. Ivana Gojo practices Hematology. She received awards:"CMS Meaningful Use Stage 1 Certification". Ivana Gojo is a published doctor and has 53 publications published. The lastest was: 'Risk-stratified outcomes of nonmyeloablative, HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide.' Dr. Ivana Gojo accepts Medicare payments and is listed with Medicare.gov.
Publications
- Risk-stratified outcomes of nonmyeloablative, HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide.
- New strategies in Acute myelogenous leukemia: leukemogenesis and personalized medicine.
- Integrated analysis of CRLF2 signaling in Acute lymphoblastic leukemia identifies Polo-like kinase 1 as a potential therapeutic target.
- Post-transplantation cyclophosphamide as single-agent GVHD prophylaxis after myeloablative conditioning and HLA-matched allografting for Acute leukemias and myelodyspl...
- Clinical and laboratory studies of the novel cyclin-dependent kinase inhibitor dinaciclib (SCH 727965) in Acute leukemias.
- Cryptic chromosome abnormalities in a patient with mixed phenotype Acute leukemia.
- Pearls and Oy-sters: The utility of cytology and flow cytometry in the diagnosis of leptomeningeal Leukemia.
- Targeting abnormal DNA double-strand break repair in tyrosine kinase inhibitor-resistant chronic myeloid Leukemias.
- Translational Phase I Trial of Vorinostat (Suberoylanilide Hydroxamic Acid) Combined with Cytarabine and Etoposide in Patients with Relapsed, Refractory, or High-Risk ...
- Phase I study of UCN-01 and perifosine in patients with relapsed and refractory Acute leukemias and high-risk myelodysplastic syndrome.
- Durable complete remission after single agent decitabine in AML relapsing in extramedullary sites after allo-SCT.
- Glans penis involvement: an under-recognized manifestation of Chronic GVHD.
- The impact of biology on the treatment of secondary AML.
- Pulmonary toxicity syndrome following CDEP (cyclophosphamide, dexamethasone, etoposide, cisplatin) chemotherapy.
- Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed Acute leukemias: a phase 1 clinical-laboratory corre...
- A phase I study of paclitaxel, UFT, and leucovorin.
- von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome.
- High-dose cyclophosphamide with or without etoposide for mobilization of peripheral blood progenitor cells in patients with multiple Myeloma: efficacy and toxicity.
- Autologous stem cell transplantation followed by consolidation chemotherapy for patients with multiple Myeloma.
- A novel NUP98-PHF23 fusion resulting from a cryptic translocation t(11;17)(p15;p13) in Acute myeloid leukemia.
- Granulomatous amebic encephalitis: an under-recognized cause of infectious mortality after hematopoietic stem cell transplantation.
- Activation of a novel palmitoyltransferase ZDHHC14 in Acute biphenotypic leukemia and subsets of Acute myeloid leukemia.
- Phase I study of the heat shock protein 90 inhibitor alvespimycin (KOS-1022, 17-DMAG) administered intravenously twice weekly to patients with Acute myeloid leukemia.
- Autologous stem cell transplantation followed by consolidation chemotherapy for relapsed or refractory Hodgkin''s Lymphoma.
- Double minute chromosomes in monoblastic (M5) and myeloblastic (M2) Acute myeloid leukemia: two case reports and a review of literature.
- Targeting vascular endothelial growth factor for relapsed and refractory adult Acute myelogenous leukemias: therapy with sequential 1-beta-d-arabinofuranosylcytosine, ...
- Racial differences in presentation, referral and treatment patterns and survival in adult patients with Acute myeloid leukemia: a single-institution experience.
- Leukopheresis for profound hyperLeukocytosis.
- Upfront therapy of Acute myeloid leukemia.
- Subdural hematomas in patients with Philadelphia chromosome-positive Acute lymphoblastic leukemia receiving imatinib mesylate in conjunction with systemic and intrathe...
- Novel agents for the treatment of Acute myeloid leukemia in the older patient.
- Single cycle of arsenic trioxide-based consolidation chemotherapy spares anthracycline exposure in the primary management of Acute promyelocytic leukemia.
- Diagnosis of biphenotypic Acute leukemia: a paradigmatic approach.
- Preclinical studies of vorinostat (suberoylanilide hydroxamic acid) combined with cytosine arabinoside and etoposide for treatment of Acute leukemias.
- Fatal subcutaneous panniculitis-like T-cell Lymphoma gamma/delta subtype (cutaneous gamma/delta T-cell Lymphoma): report of a case and review of the literature.
- Phase II trial of tipifarnib as maintenance therapy in first complete remission in adults with Acute myelogenous leukemia and poor-risk features.
- Improving treatment strategies for Acute lymphoblastic leukemia by combining immunotherapy and chemotherapy.
- A 2-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in Acute myeloid leukemia.
- Myeloid sarcomas: a histologic, immunohistochemical, and cytogenetic study.
- A phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) in combination with the nucleoside ...
- Phase I and pharmacokinetic study of Triapine, a potent ribonucleotide reductase inhibitor, in adults with advanced hematologic malignancies.
- Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed Acute leukemias.
- A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated Acute myelogenous leukemia.
- Factors affecting the pharmacokinetic profile of MS-275, a novel histone deacetylase inhibitor, in patients with Cancer.
- Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult Acute leukemias.
- Histone deacetylase inhibitor pharmacodynamic analysis by multiparameter flow cytometry.
- Phase I and pharmacologic study of infusional topotecan and Carboplatin in relapsed and refractory Acute leukemia.
- Unusual Leukemia presentations. Case 2. Granulocytic sarcoma of the colon.
- Durable molecular remissions with a single cycle of timed sequential consolidation chemotherapy in Acute promyelocytic leukemia.
- A phase II study of timed sequential therapy of Acute myelogenous leukemia (AML) for patients over the age of 60: two cycle timed sequential therapy with topotecan, ar...
- The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in multiple Myeloma cells through transcriptional repression and down-regulation of Mcl-1.
- Myeloid cell factor-1 is a critical survival factor for multiple myeloma.
Schools
University of Zagrebu Medical College
Lenox Hill Hospital
University MD School Med
Procedures Preformed
- HPC Transplantation (Stem Cell Transplant)
Conditions Treated
- Acute Leukemia
- Anemia
- Breast Cancer
- Chronic Myeloid Leukemia (CML)
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
Education
-
University of Maryland -
Lenox Hill Hospital -
University of Zagreb Faculty of Medicine
Hospital
-
Johns Hopkins Hospital
Drug Facts
| NPI NUMBER | 1194765677 | |
| NPPES Provider LastName | GOJO | |
| NPPES Provider FirstName | IVANA | |
| NPPES Provider ZIPCode | 212011544 | |
| NPPES Provider State | MD | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 20.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1194765677 |
| Last Name Of The Provider | GOJO |
| First Name Of The Provider | IVANA |
| View All |
Similar Doctors
|
|
Dr. Lorraine C. Pelosof, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michael Auerbach, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mahsa M. Mohebtash, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Yin Wu, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jenny Kim, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Saul Yanovich, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Charles S. Hesdorffer, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Adeyemisi O. Sosanya, MD |
|
|
Dr. Diana H. Griffiths, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Saira Ahmed, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sheetal Karne, MD |
|
|
Dr. Andrea C. Baines, MD |
|
|
Dr. Valentina Hoyos Velez, MD |
|
|
Dr. William H. Matsui, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Juan C. Varela, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Leo Luznik, MD |
|
|
Dr. Philip H. Imus, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Xianfeng F. Zhao, MD
This Doctor is OpenDoctor Recommended.
|